OBSErve Germany was the first observational study of belimumab as add-on treatment for
systemic lupus erythematosus (SLE) in routine clinical care in Germany, retrospectively …

Objective To generate comparative efficacy evidence of belimumab versus anifrolumab in
SLE that can inform treatment practices. Methods The SLE Responder Index (SRI)-4 …

A 20-year-old woman with SLE presents with disease flares and receives belimumab, a
monoclonal antibody that binds to B-cell activating factor, inhibiting B-cell stimulation …

Objectives To evaluate the long-term safety and efficacy of belimumab in patients with
systemic lupus erythematosus (SLE) in China. Methods In this phase 3, open-label …

Objectives To evaluate the long-term safety and efficacy of belimumab in patients with
systemic lupus erythematosus (SLE) from Japan and South Korea. Methods In this phase III …

Objectives To identify predictors of low disease activity and clinical remission following
belimumab treatment in SLE. Methods SLE patients who received belimumab 10 mg/kg (N …

Background Belimumab, the first biologic approved for the treatment of systemic lupus
erythematosus (SLE), has been shown to reduce autoantibody levels in people with SLE …

Background Belimumab is approved for the treatment of active systemic lupus
erythematosus (SLE). Although clinical trials showed a favourable benefit–risk profile …

Objective To investigate the long‐term safety and efficacy of intravenous (IV) belimumab
plus standard of care (SOC) therapy for systemic lupus erythematosus (SLE) in patients with …

Background Belimumab is the first biological agent approved for the treatment of systemic
lupus erythematosus (SLE). The efficacy and safety of belimumab for SLE patients are not …